Myelodysplastic Syndromes (MDS) Clinical Trial
Official title:
A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes
This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02550535 -
A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00186342 -
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies
|
N/A | |
| Completed |
NCT00528983 -
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
|
Phase 1 | |
| Completed |
NCT01355913 -
Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells
|
||
| Withdrawn |
NCT04985656 -
A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
|
Phase 2 | |
| Completed |
NCT01736683 -
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
|
Phase 2 | |
| Completed |
NCT02333058 -
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
|
Phase 2 | |
| Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
| Withdrawn |
NCT04395092 -
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
|
Phase 2 | |
| Completed |
NCT01885897 -
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05092451 -
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05884333 -
Cord Blood Transplant in Adults With Blood Cancers
|
Phase 2 | |
| Completed |
NCT02390414 -
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
|
||
| Completed |
NCT01326377 -
ON 01910.Na for Intermediate1-2, or High Risk Trisomy 8 Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
| Recruiting |
NCT02779569 -
A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
|
N/A | |
| Recruiting |
NCT02099669 -
Red Blood Cell Transfusion Thresholds and QOL in MDS
|
N/A | |
| Completed |
NCT01392989 -
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
|
Phase 2 | |
| Not yet recruiting |
NCT06398457 -
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
|
Early Phase 1 | |
| Recruiting |
NCT02775383 -
The National Myelodysplastic Syndromes (MDS) Study
|
||
| Recruiting |
NCT04275518 -
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
|
Phase 1 |